Pharmacokinetic—pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: A single-center, phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects
- 31 October 2009
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 31 (10) , 2258-2271
- https://doi.org/10.1016/j.clinthera.2009.10.019
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Catechol‐O‐methyltransferase and Its Inhibitors in Parkinson's DiseaseCNS Drug Reviews, 2007
- Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuationsMovement Disorders, 2005
- Safety and tolerability of COMT inhibitorsNeurology, 2004
- COMT inhibitors in Parkinson’s diseaseNeurology, 2004
- Pharmacokinetic–Pharmacodynamic Interaction Between BIA 3-202, a Novel COMT Inhibitor, and Levodopa/CarbidopaClinical Neuropharmacology, 2004
- Pharmacokinetic and Pharmacodynamic Profiles of BIA 3–202, a Novel Catechol‐O‐Methyltransferase (COMT) Inhibitor, during Multiple‐Dose Administration to Healthy SubjectsThe Journal of Clinical Pharmacology, 2003
- Kinetic inhibitory profile of BIA 3-202, a novel fast tight-binding, reversible and competitive catechol-O-methyltransferase inhibitorEuropean Journal of Pharmacology, 2003
- Management of Parkinson's disease: An evidence-based reviewMovement Disorders, 2002
- BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of l-DOPA to the brain and reduces its O-methylationEuropean Journal of Pharmacology, 2001
- Tolcapone and fulminant hepatitisThe Lancet, 1998